Biora Therapeutics, Inc. (BIOR)
(Delayed Data from NSDQ)
$0.67 USD
+0.01 (0.87%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $0.67 0.00 (-0.52%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Biora Therapeutics, Inc. [BIOR]
Reports for Purchase
Showing records 1 - 20 ( 21 total )
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
1Q24 Results; Device Pipeline Prepares for Takeoff; Topline NaviCap SAD/MAD Data in 2Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
SAD Portion of Phase 1 BT-600 Study Supports NaviCap Thesis; 2023 Results; Target Adjusted Down to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
Pipeline Approaching Inflection Point in 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
BT-600 Takes First Steps in the Clinic; Preliminary Data Expected in 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
BioJet Device Continues to Execute; AstraZeneca Disclosed as Collaborator; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
3Q23 Results; BioJet Continues to Attract Big Pharma''s Attention; NaviCap Looks to Enter the Clinic in 4Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
BT-600 Remains on Track as FDA Just Asks a Couple of Questions; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
We Project Rapidly Changing Thesis With BD a Major Factor; Reiterate Buy; Target Adjusted to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
2Q23 Results; Device Platform Stays on Course; BT-600 IND Submission and Phase 1 Start by Year-End
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
Location, Location, Location; NaviCap PoC Scintillates
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
1Q23 Results; Smart Capsule Platform Marches Forward; NaviCap IND Filing Expected in 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
PGN-062 Boosts Bioavailability of Popular Semaglutide
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
Hungry for More; Data Highlight DDS Device Function Regardless of Food Intake
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
Pre-IND Feedback Keeps Targeted Therapeutics Program on Track to Enter the Clinic in 1H23; Split-Adjusted Target to $65
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
3Q22 Results; Pipeline in Execution Mode; PGN-600 Phase 1 Study Slated to Begin by mid-2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
2Q22 Results; DDS Platform Nears Inflection Point; Phase 1 Trial in UC Expected to Begin in 1Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
Preclinical Data Highlight Efforts Towards Prepping OBDS for Primetime
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Biora Therapeutics, Inc.
Industry: Medical - Drugs
Presentations Highlight the Potential of Targeted Drug Delivery and Smart Pill Technologies
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J